Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology | Hematology | Musculoskeletal | Family Medicine
 Disease Category: Multiple Myeloma
Location: United States, CA

Trial Information

Correlating Organ Dose and Dose-Volume with Toxicities After Total Marrow Irradiation (TMI) Using Helical Tomotherapy in Patients Undergoing Hematopoetic Cell Transplantation (HCT)

You have been asked to participate in this research study because you have a diagnosis of multiple myeloma and have already agreed to participate in a research study where you will receive the chemotherapy drug, melphalan, followed by total marrow irradiation (TMI): 04064 - TANDEM HIGH-DOSE THERAPY WITH MELPHALAN AND TOTAL MARROW IRRADIATION (TMI) WITH PERIPHERAL BLOOD PROGENITOR CELL SUPPORT AND DEXAMETHASONE AND THALIDOMIDE MAINTENANCE: A PHASE I/II TRIAL. The purpose of this study is monitor side effects for the first two years after these therapies and to see if there are any relationships between side effects and the radiation therapy doses to certain organs in your body (heart, liver, lungs, kidneys, thyroid gland, and lens of the eyes). Your participation in this study is expected to last for 24 months. After your participation on this study, your medical condition will continue to be followed indefinitely.

Patient Inclusion/Exclusion Criteria:


- See http://clinicaltrials.coh.org for additional information.


City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Map

Research Center Information: City of Hope

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.